How does AbbVie’s leadership navigate the dual mission of scientific discovery and global accessibility to create a scalable, patient-centric business model?
AbbVie’s leadership combines scientific advancement and global access by ensuring a patient-focused strategy. As a Managing Director & General Manager, my perspective is that the innovation from our research should enable life-changing treatments which are accessible to patients around the world.
Our commitment to scientific discovery is significant. AbbVie invests heavily in R&D to address significant unmet medical needs including, but not limited to, immunology, oncology, neuroscience, and ophthalmology. We foster a culture that encourages curiosity, collaboration, and translational thinking, with leadership providing both the strategic direction and operational resources required to convert discovery into meaningful innovation which meets unmet medical needs.
To scale our innovations effectively, AbbVie leverages a global operational infrastructure. We have established best-in-class supply chains, digital platforms, and launch frameworks that allow us to introduce therapies efficiently across diverse regions.
Our operating model is both standardized, to uphold quality, and highly adaptable, to reflect local requirements. Patient-centricity permeates every aspect of how we operate. Real-world insights, gathered from patient feedback and support programs, drive continuous improvement of our products and the services surrounding them. Educational initiatives and digital health tools are utilized to empower patients, improve adherence, and foster better health
outcomes. This feedback-driven loop ensures we remain responsive to evolving patient needs.
Fulfilling our dual mission also requires working in partnership with a broad array of stakeholders.
We actively collaborate with government agencies, NGOs, healthcare professionals, payers, and local distributors. These partnerships are critical for navigating regulatory challenges, accelerating product registration, and ensuring that patients can benefit from the new advances. Engaging with scientific and academic institutions further accelerates discovery and extends our reach. AbbVie is steadfast in upholding ethical standards, championing sustainability, and supporting local communities.
AbbVie continuously evaluates available programs as part of our commitment to ensure the security of the supply chain and the ability to deliver medicines and products to patients. Participation in these programs requires AbbVie to work jointly with critical suppliers to perform risk assessments, and where required, we support those suppliers in developing business continuity plans to ensure security processes and procedures that protect the integrity of the supply chain are in place. Our technology platform allows us to evaluate risk across a number of critical domains, develop and implement risk mitigation plans, monitor our suppliers performance, and manage potential disruptions to our supply chain. This platform, in coordination with subject matter experts in various partner organizations within AbbVie, provides us with a broad line of sight into risks across the global supply chain on a real-time basis, offering 24/7 alerts to key decision-makers in vulnerable locations.
I see our role as inspiring and empowering teams to deliver on innovation, enabling social impact, ensuring that our business model is scalable and patient centric.
